“We are pleased that the TRACER study is evaluating the use of Fujifilm’s biomarker tests as a potential way to improve effectiveness in HCC screening in at-risk patients,” said Henry (Hidetoshi) Izawa, president and chief executive officer, FUJIFILM Healthcare Americas Corporation. “HCC is often diagnosed at an advanced stage, with limited treatment options. Our hope is that this study will further underscore the benefits of HCC-specific blood tests in the detection of early-stage HCC, and patients will benefit from earlier diagnosis and treatment options.”
The use of the Fujifilm’s biomarkers in the GALAD model is a novel concept and for research use only.
TRACER is supported by a grant within the Early Detection Research Network, a program of the National Cancer Institute, National Institutes of Health.
Ad Statistics
Times Displayed: 48800
Times Visited: 1523 Keep biomedical devices ready to go, so care teams can be ready to care for patients. GE HealthCare’s ReadySee™ helps overcome frustrations due to lack of network and device visibility, manual troubleshooting, and downtime.
[i] Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, et al. 2024. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.who.int/today, accessed [11 April 2025].
[ii] Hanif H, Ali MJ, Susheela AT, Khan IW, Luna-Cuadros MA, et al. 2022. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. World J Gastroenterol 28(2):216-229,PMID: 35110946.
[iii] Yang JD, Addissie BD, Mara KC, Harmsen WS, Dai J, et al. 2018. GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score. Cancer Epidemiol Biomarkers Prev 28(3):531-538, PMID: 30464023.
About Fujifilm
FUJIFILM Healthcare Americas Corporation is a comprehensive healthcare company that has an extensive range of technology and expertise in the detection, diagnosis, and treatment of diseases. Fujifilm’s innovative portfolio includes solutions spanning diagnostic imaging, enterprise imaging, endoscopic imaging, surgical imaging, and in-vitro diagnostics. The Non-Destructive Testing group delivers radiography solutions to ensure high accuracy inspection of transportation infrastructure, and assets within aerospace, and oil and gas industries.
Back to HCB News
